A retirement at Pfizer, a new CEO at B-MS and appointments at Mylan, Archimedes and Kinex – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Pharmaceutical companies of the united states

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a retirement at Pfizer, a new CEO at B-MS and appointments at Mylan, Archimedes and Kinex.

Lamberto Andreotti ​has been appointed as CEO of Bristol-Myers Squibb​. Andreotti will begin the role when James Cornelius​ retires as CEO. Cornelius will remain as chairman at the request of the B-MS’ board.

Andreotti has worked at B-MS for 12 years. Before joining the company he worked at KABI Pharmacia and Pharmacia & Upjohn.

Archimedes Pharma​ has secured £65m ($97m) in new funding and appointed a new CEO as it targets the US market. Jeffrey Buchalter ​has been named as president and CEO having recently resigned from the same positions at Enzon. Buchalter has also worked at Wyeth.

William Ringo​, senior vice president (SVP), worldwide business development, strategy and innovation at Pfizer​, is to retire. Ringo joined Pfizer in 2008, having spent 28 years at Eli Lilly, and is credited with helping the company connect with expanding opportunities in biotech.

Mylan​ has named John Sheehan​ as executive VP and chief financial officer. Sheehan has more than 30 years of experience in global corporate finance at companies including Delphi Automotive and KPMG.

Rudolf Kwan​ has joined Kinex Pharmaceuticals​. Kwan has more than 20 years experience in clinical operations, most recently at Schering Plough. He has also worked at Chiron and SmithKline Beecham.

Aegate ​has appointed Trevor Jones ​to its executive board. Jones has more than 40 years experience in the pharma industry, holding positions at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Allergan and Synexus.

Stephen Hitchcock​ has been named as SVP, drug discovery at Envoy Therapeutics​. Hitchcock joins Envoy from Amgen where he spent six years. He also worked at Eli Lilly for 10 years.

Garnet BioTherapeutics​ has appointed Sanjay Batra​ as SVP, development. Batra has more than 15 years experience in the pharma and biotech sectors, including nine years at Johnson & Johnson and a period at Bracco Diagnostics.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more